PT3752190T - Regime anticancerígeno usando anticorpos anti-cd47 e anti-cd20 - Google Patents
Regime anticancerígeno usando anticorpos anti-cd47 e anti-cd20Info
- Publication number
- PT3752190T PT3752190T PT197098189T PT19709818T PT3752190T PT 3752190 T PT3752190 T PT 3752190T PT 197098189 T PT197098189 T PT 197098189T PT 19709818 T PT19709818 T PT 19709818T PT 3752190 T PT3752190 T PT 3752190T
- Authority
- PT
- Portugal
- Prior art keywords
- antibodies
- cancer regimen
- regimen
- cancer
- Prior art date
Links
- 230000001093 anti-cancer Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/804—Blood cells [leukemia, lymphoma]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862629340P | 2018-02-12 | 2018-02-12 | |
| US201862678468P | 2018-05-31 | 2018-05-31 | |
| US201862743060P | 2018-10-09 | 2018-10-09 | |
| US201862743875P | 2018-10-10 | 2018-10-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3752190T true PT3752190T (pt) | 2022-11-18 |
Family
ID=65718081
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT197098189T PT3752190T (pt) | 2018-02-12 | 2019-02-11 | Regime anticancerígeno usando anticorpos anti-cd47 e anti-cd20 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11891450B2 (pt) |
| EP (2) | EP3752190B1 (pt) |
| JP (2) | JP7343528B2 (pt) |
| KR (1) | KR20200119834A (pt) |
| CN (1) | CN111699005A (pt) |
| AU (1) | AU2019218271B2 (pt) |
| CA (1) | CA3090489A1 (pt) |
| ES (1) | ES2927305T3 (pt) |
| PL (1) | PL3752190T3 (pt) |
| PT (1) | PT3752190T (pt) |
| SI (1) | SI3752190T1 (pt) |
| WO (1) | WO2019157432A1 (pt) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2796378T3 (es) | 2016-01-11 | 2020-11-26 | Forty Seven Inc | Anticuerpos monoclonales anti-cd47 humanizados, de ratón o químicos |
| WO2018075960A1 (en) | 2016-10-21 | 2018-04-26 | Tioma Therapeutics, Inc. | Therapeutic cd47 antibodies |
| PT3752190T (pt) | 2018-02-12 | 2022-11-18 | Forty Seven Inc | Regime anticancerígeno usando anticorpos anti-cd47 e anti-cd20 |
| US20220119523A1 (en) * | 2019-02-08 | 2022-04-21 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of cutaneous t cell lymphoma with targeting of cd47 pathway |
| MX2021014627A (es) * | 2019-05-31 | 2022-01-06 | Alx Oncology Inc | Polipeptidos de citocinas enmascaradas. |
| WO2021046216A1 (en) * | 2019-09-03 | 2021-03-11 | Arch Oncology, Inc. | Methods for identifying biomarkers to predict treatment response |
| CN114786776A (zh) | 2019-09-18 | 2022-07-22 | 拉姆卡普生物阿尔法股份公司 | 针对ceacam5和cd3的双特异性抗体 |
| JP2022552748A (ja) * | 2019-10-31 | 2022-12-19 | フォーティ セブン， インコーポレイテッド | 抗ｃｄ４７及び抗ｃｄ２０による血液癌の治療 |
| US20210221886A1 (en) * | 2019-12-05 | 2021-07-22 | Sorrento Therapeutics, Inc. | Compositions and Methods Comprising an Anti-CD47 Antibody in Combination with a Tumor Targeting Antibody |
| EP4089114A1 (en) * | 2020-01-09 | 2022-11-16 | Innovent Biologics (Suzhou) Co., Ltd. | Application of combination of anti-cd47 antibody and anti-cd20 antibody in preparation of drugs for preventing or treating tumors |
| US20230090868A1 (en) * | 2020-01-31 | 2023-03-23 | Seagen Inc. | Anti-cd30 antibody-drug conjugates and their use for the treatment of non-hodgkin lymphoma |
| JPWO2021157650A1 (pt) * | 2020-02-05 | 2021-08-12 | ||
| WO2021219092A1 (en) * | 2020-04-30 | 2021-11-04 | I-Mab Biopharma Co., Ltd. | Pharmaceutical compositionscontaining anti-cd47 antibodies |
| CN112578117B (zh) * | 2021-02-22 | 2021-05-25 | 信纳克(北京)生化标志物检测医学研究有限责任公司 | 抗体组合物及其筛查移植后淋巴细胞增殖性疾病的应用 |
| WO2024010842A1 (en) * | 2022-07-07 | 2024-01-11 | The Board Of Trustees Of The Leland Stanford Junior University | Targeting cells with a combination of cxcr2 inhibition and cd47 blockade |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2226962A1 (en) | 1998-02-16 | 1999-08-16 | Marie Sarfati | Use of binding agents to cd47 and its ligands in the treatment or the prophylaxis of various inflammatory, autoimmune and allergic diseases and in the treatment of graft rejection |
| GB9930706D0 (en) | 1999-12-24 | 2000-02-16 | Medical Res Council | Composition for inhibiting macrophage activity |
| WO2003072736A2 (en) | 2002-02-21 | 2003-09-04 | Duke University | Reagents and treatment methods for autoimmune diseases |
| CA2494104A1 (en) | 2002-07-31 | 2004-04-22 | Seattle Genetics, Inc. | Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders |
| CA2545166A1 (en) | 2003-11-11 | 2005-05-19 | Chugai Seiyaku Kabushiki Kaisha | Humanized anti-cd47 antibody |
| WO2007053189A2 (en) | 2005-06-01 | 2007-05-10 | Northwestern University | Compositions and methods for altering immune function |
| US20090191202A1 (en) | 2005-09-29 | 2009-07-30 | Jamieson Catriona Helen M | Methods for manipulating phagocytosis mediated by CD47 |
| WO2008121821A1 (en) | 2007-03-28 | 2008-10-09 | Biogen Idec Inc. | Treatment of hodgkins lymphoma |
| EP4470556A3 (en) | 2008-01-15 | 2025-04-23 | The Board of Trustees of the Leland Stanford Junior University | Markers of acute myeloid leukemia stem cells |
| DK2242512T3 (en) | 2008-01-15 | 2016-06-06 | Univ Leland Stanford Junior | Method for manipulating phagocytosis mediated by CD47 |
| EP2111869A1 (en) | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
| EP2477648B1 (en) | 2009-09-15 | 2022-07-20 | The Board of Trustees of the Leland Stanford Junior University | Synergistic anti-cd47 therapy for hematologic cancers |
| EP2506871B1 (en) | 2009-11-30 | 2016-10-19 | Janssen Biotech, Inc. | ANTIBODY Fc MUTANTS WITH ABLATED EFFECTOR FUNCTIONS |
| WO2011143624A2 (en) | 2010-05-14 | 2011-11-17 | The Board Of Trustees Of The Leland Stanford Junior University | Humanized and chimeric monoclonal antibodies to cd47 |
| WO2013056352A1 (en) | 2011-10-19 | 2013-04-25 | University Health Network | Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers |
| JP6460796B2 (ja) | 2012-01-17 | 2019-01-30 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 高親和性ｓｉｒｐ−アルファ試薬 |
| CA3145468A1 (en) | 2012-12-17 | 2014-06-26 | Trillium Therapeutics Inc. | Treatment of cd47+ disease cells with sirp alpha-fc fusions |
| JP2016507555A (ja) | 2013-02-06 | 2016-03-10 | インヒブルクス エルピー | 血小板非減少性かつ赤血球非減少性ｃｄ４７抗体及びその使用方法 |
| EP3792285A1 (en) * | 2013-03-15 | 2021-03-17 | The Board of Trustees of the Leland Stanford Junior University | Methods for achieving therapeutically effective doses of anti-cd47 agents |
| CN103665165B (zh) | 2013-08-28 | 2016-02-24 | 江苏匡亚生物医药科技有限公司 | 一种靶向人CD47-SIRPα信号通路的双特异性抗体及其制备方法和用途 |
| AU2015204766B2 (en) | 2014-01-08 | 2020-08-13 | The Board Of Trustees Of The Leland Stanford Junior University | Targeted therapy for small cell lung cancer |
| WO2015138600A2 (en) | 2014-03-11 | 2015-09-17 | The Board Of Trustees Of The Leland Stanford Junior University | Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies |
| CN106535914B (zh) | 2014-08-08 | 2021-08-27 | Alx 肿瘤生物技术公司 | SIRP-α变体构建体及其用途 |
| BR112018001353A2 (pt) | 2015-08-07 | 2018-09-11 | Alexo Therapeutics, Inc. | construtos tendo um domínio de sirp-alfa ou variante do mesmo |
| HUE071893T2 (hu) | 2015-10-21 | 2025-09-28 | Ose Immunotherapeutics | Eljárások és készítmények makrofágpolarizáció módosítására proinflammatóriás sejtekbe, rák kezelésére |
| KR20250004896A (ko) | 2015-12-11 | 2025-01-08 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | Cd47 및 egfr의 이중 표적화를 이용한 암의 치료 |
| ES2796378T3 (es) | 2016-01-11 | 2020-11-26 | Forty Seven Inc | Anticuerpos monoclonales anti-cd47 humanizados, de ratón o químicos |
| EP3405499A4 (en) | 2016-01-21 | 2020-03-18 | The Board of Trustees of the Leland Stanford Junior University | TREATMENT OF CANCER WITH COMBINATIONS OF IMMUNOREGULATORS |
| WO2017177333A1 (en) | 2016-04-15 | 2017-10-19 | Trillium Therapeutics Inc. | Macrophage stimulation in cd47 blockade therapy |
| US11472878B2 (en) * | 2016-04-15 | 2022-10-18 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for determining and achieving therapeutically effective doses of anti-CD47 agents in treatment of cancer |
| CN106084052B (zh) * | 2016-06-17 | 2019-12-27 | 长春金赛药业股份有限公司 | 抗cd47单克隆抗体及其应用 |
| US10961318B2 (en) | 2017-07-26 | 2021-03-30 | Forty Seven, Inc. | Anti-SIRP-α antibodies and related methods |
| SI3697819T1 (sl) | 2017-10-18 | 2023-01-31 | Forty Seven, Inc. | Zdravljenje raka jajčnikov z anti-CD47 in anti-PD-L1 |
| SI3697817T1 (sl) | 2017-10-18 | 2023-01-31 | Forty Seven, Inc. | Terapija za raka jajčnikov na osnovi sredstva proti CD47 |
| PT3752190T (pt) | 2018-02-12 | 2022-11-18 | Forty Seven Inc | Regime anticancerígeno usando anticorpos anti-cd47 e anti-cd20 |
-
2019
- 2019-02-11 PT PT197098189T patent/PT3752190T/pt unknown
- 2019-02-11 EP EP19709818.9A patent/EP3752190B1/en active Active
- 2019-02-11 US US16/272,350 patent/US11891450B2/en active Active
- 2019-02-11 JP JP2020564800A patent/JP7343528B2/ja active Active
- 2019-02-11 CN CN201980012504.6A patent/CN111699005A/zh active Pending
- 2019-02-11 CA CA3090489A patent/CA3090489A1/en active Pending
- 2019-02-11 PL PL19709818.9T patent/PL3752190T3/pl unknown
- 2019-02-11 AU AU2019218271A patent/AU2019218271B2/en active Active
- 2019-02-11 ES ES19709818T patent/ES2927305T3/es active Active
- 2019-02-11 WO PCT/US2019/017466 patent/WO2019157432A1/en not_active Ceased
- 2019-02-11 EP EP22183160.5A patent/EP4129336B1/en active Active
- 2019-02-11 KR KR1020207025511A patent/KR20200119834A/ko not_active Ceased
- 2019-02-11 SI SI201930333T patent/SI3752190T1/sl unknown
-
2023
- 2023-06-30 JP JP2023108143A patent/JP2023115349A/ja not_active Ceased
- 2023-12-19 US US18/389,605 patent/US20240218077A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019218271B2 (en) | 2024-12-12 |
| CN111699005A (zh) | 2020-09-22 |
| US11891450B2 (en) | 2024-02-06 |
| PL3752190T3 (pl) | 2022-11-07 |
| KR20200119834A (ko) | 2020-10-20 |
| EP3752190A1 (en) | 2020-12-23 |
| CA3090489A1 (en) | 2019-08-15 |
| US20190248915A1 (en) | 2019-08-15 |
| JP7343528B2 (ja) | 2023-09-12 |
| EP4129336B1 (en) | 2025-05-07 |
| SI3752190T1 (sl) | 2022-11-30 |
| JP2023115349A (ja) | 2023-08-18 |
| JP2021515805A (ja) | 2021-06-24 |
| ES2927305T3 (es) | 2022-11-04 |
| AU2019218271A1 (en) | 2020-09-10 |
| EP4129336A1 (en) | 2023-02-08 |
| WO2019157432A8 (en) | 2020-06-25 |
| WO2019157432A1 (en) | 2019-08-15 |
| US20240218077A1 (en) | 2024-07-04 |
| EP3752190B1 (en) | 2022-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI3752190T1 (sl) | Shema zdravljenja proti raku z uporabo protiteles proti CD47 in proti CD20 | |
| ZA202105676B (en) | Anti-trem2 antibodies and related methods | |
| IL290457A (en) | Antibodies and their conjugates | |
| IL272218A (en) | ANTI-SIRP-ALPHA ANTIBODIES AND RELATED METHODS | |
| SG11202000053TA (en) | Anti-cd47 antibodies and uses thereof | |
| IL255526B (en) | cd123 antibodies and their conjugates | |
| IL264970A (en) | Anti-tim-3 antibodies and their use | |
| IL267129A (en) | New T-cell receptors and immunotherapy using them | |
| PT3347379T (pt) | Anticorpos anti-tígitos, anticorpos anti-pvrig e as suas combinações | |
| RS62498B1 (sr) | T-ćelijski receptori i imunoterapija u kojoj se koriste | |
| IL271222A (en) | Dosing regimens for anti-tim-3 antibodies and their uses | |
| EP3541840C0 (en) | ANTI-HLA-G ANTIBODIES AND ITS USE | |
| SG10202109691UA (en) | Anti-pacap antibodies and uses thereof | |
| IL265689A (en) | Antibodies against il-33 and their use | |
| ZA201900664B (en) | T cell receptors and immune therapy using the same | |
| ZA201801607B (en) | Antigen receptors and uses thereof | |
| IL252430A0 (en) | Antibodies, uses and methods | |
| IL266082A (en) | Anti-chikv antibodies and their use | |
| IL266049A (en) | Antibodies against o1 and their uses | |
| IL264417A (en) | Anti-o2 antibodies and their uses | |
| IL267340A (en) | Monoclonal antibodies against pcna and their use | |
| IL266059A (en) | Anti-rankl antibodies and their uses | |
| IL264855B1 (en) | T-cell receptors and immunotherapy using them | |
| HK40020419A (en) | Dosage regimens for anti-tim-3 antibodies and uses thereof | |
| GB201618515D0 (en) | Combinations comprising antibodies, uses and methods |